Previous 10 | Next 10 |
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS) , iBio (NYSEMKT: IBIO) , and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. One common catalyst seems to be the secondary-share issues anno...
Marinus Pharmaceuticals ([[MRNS]] -10.0%) announces the pricing of an underwritten public offering of 5M shares of its common stock for gross proceeds of $70M.Underwriters granted a 30-day option to purchase up to an additional 750,000 shares of common stock.Net proceeds of the offering to fu...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $7...
Marinus Pharmaceuticals (MRNS) has announced an underwritten public offering of its common stock.Volume, price are yet to be determined. For further details see: Marinus Pharma launches equity offering
Marinus Pharmaceuticals, Inc . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be ...
Top-line data from the Marigold Study in CDKL5 deficiency disorder (CDD) presented as late breaking results during AES scientific sessions; An analysis of data from the Marigold Study shows a consistent efficacy signal across multiple subgroups, including a 36.7% estimated differenc...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the launch of an expanded access program (EAP) that will allow the company to offer ganaxolone to patients ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in ...
Six Additional Posters to be Presented in the Marinus Scientific Exhibit Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that four abstract...
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2020 Earnings Conference Call November 09, 2020 04:30 PM ET Company Participants Sasha Damouni Ellis - VP, IR and Corporate Communications Scott Braunstein - CEO Joe Hulihan - CMO Edward Smith - VP and CFO Conference Call Participants Joseph Thome - Cow...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...